Bausch & Lomb BLCO announced an agreement with Novartis to acquire dry eye drug Xiidra (along with a few early-stage eye care products) for $1.75 billion in upfront cash and potential sales-based ...
Please provide your email address to receive an email when new articles are posted on . Bausch + Lomb has acquired Xiidra, and other dry eye disease assets, from Novartis. Xiidra may achieve better ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results